Sintilimab plus bevacizumab before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults 18 or older with a type of liver cancer called hepatocellular carcinoma (HCC) that can be surgically removed (resectable) and is beyond the Milan criteria.
- You must not have had any previous treatment for your liver cancer.
- Your liver function must be good (Child-Pugh class A) and you should be in relatively good health (performance status 0-1).
- No history of bleeding from your stomach or esophagus (varices), blood clots, or uncontrolled high blood pressure.
- You cannot have other active cancers, serious infections, or autoimmune diseases requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (bevacizumab and sintilimab) versus a standard procedure (TACE) for people with intermediate-stage liver cancer that is too large or widespread for surgery. The goal is to see if the drug combination works better at controlling the cancer.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
This trial tests whether the immunotherapy drug Sintilimab, given after surgery, can help prevent liver cancer from coming back in people whose tumors had tiny blood vessel invasion. It is for patients who have fully recovered from surgery and have not had other cancer treatments before.
This trial tests whether a combination of two drugs (sintilimab and lenvatinib) given after surgery can help prevent liver cancer from coming back in people who had a tumor growing into the portal vein (a major blood vessel in the liver). You may join if you recently had successful surgery and haven't had other treatments yet.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.